Oncolytics Biotech Inc T.ONC

OVs improve cancer immunotherapy by reprogramming TME

[Noteable]

December 08, 2023 -  Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment. 

Immunotherapies using immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy have achieved successful results against several types of human tumors, particularly hematological malignancies. However, their clinical results for the treatment of solid tumors remain poor and unsatisfactory. The immunosuppressive tumor microenvironment (TME) plays an important role by interfering with intratumoral T-cell infiltration, promoting effector T-cell exhaustion, upregulating inhibitory molecules, inducing hypoxia, and so on.  

Oncolytic virotherapy (OV) contributes to the reprogramming of the TME, thus synergizing the functional effects of current ICIs and CAR T-cell therapy to overcome resistant barriers in solid tumors. 

While other OV companies are theorizing on their prospects, ONCY has CONFIRMED  that pelareorep is able to remodel the TME for the effective administration of CPI therapy.


https://pubmed.ncbi.nlm.nih.gov/38062315/

[Noteable]

ONCY has been using Nanostring  technology to map the effect of pelareorep on the TME. The Nanostring  panels contain the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.   Nanostring uses SNP sequencing for

[ScootsMcgoots]

Yes we all know pela works, remodels microevironment converts macrophages from m1 to m2, etc etc, no denying it. How do you know that this will be the preferred immunotherapy option used in the clinic? There's dozens of immunotherapies presently in development not to mention countless targeted therapies. CLTA-4 is rather promising in GI, numerous others including an ongoing collaboration

[Normandt]

Why would they only prefer one? There are currently 50 kinds of chemotherapy divided into 4 types and chosen according to the patient, their cancer, previous treatments, stage, age, etc.... why it would be different for immunotherapies. As long as it works positively in synergy with something else (chemotherapy or whatever), there are companies that will want to have it in their choice of

[Noteable]

McGroots , So tell me what you know about everything you've posted. Tell me about the lack of successes with each of the 'promising' agents that you've commented on, particularly the adenovirus LOAd703 and the CPI CTLA-4. Are you here to pump both? And what are the clinical results with each? Nil?

[Noteable]

The adenovirus LOAd703 is administered by intratumoral (IT) injection. I guess you haven't read what I've posted on this matter in the past, before you mounted your attack, and obviously don't know that Big Pharma won't touch IT administered drugs because of the complexity of requiring extensive prep time and the use of surgical suites to deliver that form of drug. That's just

[Noteable]

Mcroots, show me the work that other OV companies have completed to prove their ability to remodel the TME, other than their rhetoric following the release of ONCYs clinical trial results on pelareoreps ability to convert an otherwise immunosuppressive TME and prime the TME in advance of CPI administration. 

[ScootsMcgoots]

I'll ignore the personal words. Sure systemic admin is an advantage. Not a fait accompli though. Opinions may change with good enough results. Intratumoral is also showing the ability to go after Mets in some situations. CG therapeutics is showing 60%+ CR rate in bladder cancer for intratumoral admin. Immunogene on bile duct cancer intratumoral has a CR in a 1/1 patient population.  

[Noteable]

Once again McGroots, you very obviously haven't read my previous posts. Consequently, I can't make your ignorance any more personal than that, other than to quote ”Forrest Gump” -  ”Stupid is as stupid does”. 

[Onc2hope]

So b4 notable calls me shorter or hedge fund hack my investment is about $30k at $3.63 cdn avg over past 10-12 years.  its so clear that noteable is a shill for the company. Any querie is met with disdain never a response of any value (which i expect shortly) knows all about other therapies and interactions. There should be no way anyone talks continually about how great oncy is doing

[Lesalpes29]

If hedge funds are so successfull it's only because of ower CEO of the year!

[ScootsMcgoots]

Yeah there is something seriously off about Noteable. 

[Noteable]

Anyone with ONC in their name has proven to be a troll. Thats how they track their screen names to the appropriate board. ONC2hope became alive here at the same time Buckhenry did. https://stockhouse.com/members/onc2hope

[Onc2hope]

I predicted it!! Just signed up today so do t know w t f you are talking about. You lie as easily as breath!!

[Onc2hope]

Or as notable has said..'Stupid is as stupid does'..

[Noteable]

ONC2hope - 'Stupid is as stupid does' - you became a member on December 11, 2023 . Onc2hope    Member Since: December 11, 2023 Reputation 2 Followers 0 Following 0 More about Reputation Community

[Onc2hope]

Keep it up dummy!! How did i come with buckhenry if hes been posting for months!! Try to keep it togethet jeez